Oral tetracycline vs topical clindamycin
Physician global assessment VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 34 participantsLow
Findings
What do systematic reviews say?
64 questions · 65 findings · 10 reviews · Headline outcomes only
No studies found 19 · 29.2%GRADE not reported 4 · 6.2%Very low 10 · 15.4%Low 18 · 27.7%Moderate 14 · 21.5%High 0 · 0%
Macrolide+tetracycline vs macrolides
Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 187 participantsVery low
Macrolide+tetracycline vs macrolides
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyOR 1 [0.52, 1.93]1 study · 198 participantsVery low
Macrolide+tetracycline vs macrolides
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 182 participantsVery low
Macrolide+tetracycline vs macrolides
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyOR 1.63 [0.38, 7.02]1 study · 198 participantsVery low
Macrolide+tetracycline vs macrolides
Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Nicotinamide plus tetracycline vs prednisone
Disease control: complete response at 8 weeks: excluding dropouts · bullous pemphigoid
It is very uncertain whether nicotinamide plus tetracycline changes disease control: complete response at 8 weeks: excluding dropouts compared with prednisone (very low certainty).
1 finding from 1 review
- RR 2.5 [0.37, 16.89]1 study · 18 participantsVery low
Nicotinamide plus tetracycline vs prednisone
Mortality at 6 months · bullous pemphigoid
It is very uncertain whether nicotinamide plus tetracycline changes mortality at 6 months compared with prednisone (very low certainty).
1 finding from 1 review
- RR 0.18 [0.01, 3.85]1 study · 18 participantsVery low
Nicotinamide plus tetracycline vs prednisone
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Nicotinamide plus tetracycline vs prednisone
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Macrolides vs tetracycline
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyOR 0.44 [0.14, 1.38]1 study · 50 participantsLow
Quinolone vs tetracycline
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyOR 0.44 [0.14, 1.38]1 study · 50 participantsLow
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
It is very uncertain whether regimens containing macrolides (azithromycin) changes clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (very low certainty).
2 findings from 1 review
- RR 1.18 [0.89, 1.55]Studies not reportedVery low
- RR 1.35 [1.1, 1.67]Studies not reportedModerate
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Clinical cure according to criteria established by study authors Severe PID · women with PID
Regimens containing macrolides (azithromycin) showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (low certainty).
1 finding from 1 review
- RR 1 [0.96, 1.05]Studies not reportedLow
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID
Regimens containing macrolides (azithromycin) showed no clear difference in adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing tetracycline (doxycycline) (low certainty).
1 finding from 1 review
- RR 0.71 [0.38, 1.34]Studies not reportedLow
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Microbiological clearance · women with PID
Regimens containing macrolides (azithromycin) showed no clear difference in microbiological clearance compared with regimens containing tetracycline (doxycycline); GRADE not reported.
1 finding from 1 review
- RR 1.02 [0.98, 1.06]Studies not reportedGRADE not reported
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Laparoscopic evidence of resolution of PID based on physician opinion · women with PID
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Length of stay · women with PID
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)
Fertility outcome · women with PID
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral azithromycin vs topical tetracycline
Active trachoma · people (any age) with active trachoma
1 finding from 1 review
- no estimate extracted3 studies · 6002 participantsLow